Share ownership Moderna, Inc.

MRNA

US60770K1079

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 05/06/2026 BST			5-day change	1st Jan Change
47.44 ^USD	-8.04%		+0.53%	+60.87%

06-04	What Bundibugyo Ebola vaccines and treatments are under development	RE
06-03	HEALTH ROUNDS-Radiation-emitting implant improves outcomes after brain cancer surgery	RE

Share class: Moderna, Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	396,786,259	367,793,950 ( 92.69 %)	0	92.69 %

Major shareholders: Moderna, Inc.

Name	Equities	%	Valuation
Fidelity Management & Research Co. LLC 11.52 %	45,672,024	11.52 %	2 098 M $
BlackRock Advisors LLC 6.084 %	24,127,684	6.084 %	1 108 M $
Vanguard Capital Management LLC 5.767 %	22,872,458	5.767 %	1 051 M $
Stéphane Bancel 5.538 %	21,963,357	5.538 %	1 009 M $
Baillie Gifford & Co. 5.039 %	19,985,876	5.039 %	918 M $
Capital Research & Management Co. (World Investors) 4.715 %	18,697,694	4.715 %	859 M $
Vanguard Portfolio Management LLC 3.938 %	15,616,367	3.938 %	717 M $
STATE STREET CORPORATION 3.747 %	14,861,409	3.747 %	683 M $
Geode Capital Management LLC 2.379 %	9,435,132	2.379 %	433 M $
Two Sigma Investments LP 2.291 %	9,086,404	2.291 %	417 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Banco JPMorgan SA 0.000439 %	34,827	0.000439 %	77 729 $
Banco Santander Brasil SA (Private Banking) 0.000006 %	451	0.000006 %	1 007 $

Breakdown by shareholder type

Institutional	68.53%
Individuals	6.69%
Others	5.56%
State Street Corp.	3.75%
Merck & Co., Inc.	0.58%
Schweizerische Nationalbank	0.18%
Governments	0.1%
Manulife Financial Corp.	0.08%
SEI Investments Co.	0.05%
Banco Bilbao Vizcaya Argentaria SA	0.02%
Fifth Third Bancorp	0.02%
Sumitomo Mitsui Trust Group, Inc.	0.01%
Meitav Investment House Ltd.	0.01%
The Allstate Corp.	0.01%
Unknown	14.41%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	62.14%
United Kingdom	10.79%
Individuals	6.69%
Switzerland	1.3%
Canada	1.02%
Norway	0.71%
Australia	0.64%
Brazil	0.63%
France	0.59%
Singapore	0.18%
Hong Kong	0.16%
Japan	0.15%
Luxembourg	0.14%
Ireland	0.11%
Germany	0.1%
Spain	0.09%
Sweden	0.03%
Czech Republic	0.03%
China	0.03%
Israel	0.01%
Denmark	0.01%
Cayman Islands	0.01%
Netherlands	0.01%
Greece	0.01%

Based on 1000 largest holdings

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (96.1%); - revenue from collaboration agreements (1.5%); - revenue from royalties and licensing (1.3%); - revenue from grants (1.1%). At the end of 2024, the group's portfolio comprises 37 products in clinical development, of which 10 in phase I, 18 in phase II and 9 in phase III, 3 products in preclinical development, and 4 products in commercial phase. Net sales are distributed geographically as follows: the United States (55.1%), Europe (18.5%) and other (26.4%).

Employees

4,700

Sector

Pharmaceuticals

More about the company